Welcome to our dedicated page for InMed Pharmaceuticals Common Shares news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals Common Shares stock.
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a leading Canadian clinical-stage biopharmaceutical company at the forefront of cannabinoid research and development. Specializing in the creation of novel therapies, InMed harnesses the extensive pharmacology of cannabinoids, combined with cutting-edge drug delivery systems.
InMed's innovative approach includes a robust product pipeline featuring:
- INM-755: A topical cream for the treatment of epidermolysis bullosa, a rare skin condition.
- INM-088: An ophthalmic formulation targeting glaucoma to preserve retinal function.
- INM-901: A promising treatment for Alzheimer's disease, showing multiple mechanisms of action to improve cognitive and memory functions.
- INM-089: Aimed at treating age-related macular degeneration (AMD), focusing on retinal protection and functionality.
The company's proprietary IntegraSyn manufacturing system ensures the production of high-quality pharmaceutical-grade cannabinoids, positioning them as a key player in the industry.
InMed's recent achievements include:
- Completion of a Phase 2 clinical trial for INM-755.
- Initiation of two new preclinical programs for Alzheimer's and AMD.
- Strong financial performance with significant revenue growth from its subsidiary BayMedica, which supplies rare cannabinoids to the health and wellness sector.
InMed's commitment to advancing cannabinoid science is evident through its strategic partnerships, rigorous research, and innovative product development, making significant strides in treating diseases with high unmet medical needs. For more information, visit www.inmedpharma.com.
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) will participate in the Water Tower Research Fireside Chat Series on January 25, 2024, to discuss its pharmaceutical pipeline in Alzheimer's and ocular, upcoming 2024 milestones, and the role of cannabinoids in Alzheimer's treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. outlines key accomplishments from 2023 and provides strategic priorities for 2024, including the advancement of INM-901 as a treatment for Alzheimer's Disease, the treatment of Age-related Macular Degeneration with INM-089, and seeking partnerships for INM-755 in Dermatology. BayMedica subsidiary continues to focus on revenue growth and market expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) confirms approval of all matters at the annual general meeting of shareholders, including the election of all director nominees. A total of 1,292,647 common shares, representing approximately 38.84% of the Company's issued and outstanding common shares, were represented at the Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) announces the launch of INM-089, a cannabinol (CBN) analog, to investigate its effects in the treatment of Age-related Macular Degeneration (AMD). INM-089 preserved retinal function in an in vivo AMD disease model and improved the thickness of the outer nuclear layer of the retina. The company aims to advance INM-089 to additional in vivo studies as part of the preclinical development program to address the unmet medical need in AMD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.62%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) reports financial results for Q1 FY2024, highlighting advancements in pharmaceutical programs, commercial operations, and a successful financing round. The company's INM-901 program shows promise in targeting Alzheimer's disease, while the INM-755 CBN cream demonstrates potential for broader applications. BayMedica, the company's commercial subsidiary, experiences robust revenue growth. Financially, the company records a net loss of $2.5M for Q1 FY2024, with a decrease in cash and cash equivalents compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. announced that their Phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with epidermolysis bullosa has been accepted as an oral presentation at the 12th World Congress on Itch. The study showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
Rhea-AI Summary
InMed Pharmaceuticals has closed its previously announced offering for the issuance and sale of pre-funded warrants and preferred investment options. The offerings raised approximately $5.2 million in gross proceeds, which will be used for pipeline development, commercial sales, and general working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.93%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. has entered into definitive agreements for a private placement, issuing 3,012,049 common shares and preferred investment options. The offerings are expected to raise approximately $5.2 million, with the net proceeds to be used for pipeline development and commercial sales of rare cannabinoids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.17%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals has selected INM-901 as its lead Alzheimer's disease drug candidate after positive results from proof-of-concept studies. INM-901 showed potential in targeting biological pathways associated with Alzheimer's and demonstrated favorable results in preclinical studies. The next stage will include advanced preclinical studies and drug development activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
70.52%
Tags
News
Rhea-AI Summary
InMed Pharmaceuticals Inc. reports $4.1M revenues in fiscal year 2023, a 280% increase over the previous year, and $2.3M revenues in fiscal Q4 2023, a 123% increase QoQ. Completed Phase 2 Clinical Trial for anti-itch cream. Launches INM-900 series program targeting neurodegenerative diseases. Cash, cash equivalents, and short-term investments at $9.0M as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
FAQ
What is the current stock price of InMed Pharmaceuticals Common Shares (INM)?
The current stock price of InMed Pharmaceuticals Common Shares (INM) is $4.66 as of November 22, 2024.
What is the market cap of InMed Pharmaceuticals Common Shares (INM)?
The market cap of InMed Pharmaceuticals Common Shares (INM) is approximately 3.4M.
What is InMed Pharmaceuticals Inc.?
InMed Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in the research, development, and manufacturing of novel cannabinoid-based therapies.
What products are in InMed's pipeline?
InMed's product pipeline includes INM-755 for epidermolysis bullosa, INM-088 for glaucoma, INM-901 for Alzheimer's disease, and INM-089 for age-related macular degeneration.
What is the IntegraSyn manufacturing system?
IntegraSyn is InMed's proprietary manufacturing system designed to produce high-quality pharmaceutical-grade cannabinoids efficiently.
What recent achievements has InMed made?
Recent achievements include completing a Phase 2 clinical trial for INM-755, launching preclinical programs for Alzheimer's and AMD, and significant revenue growth from BayMedica.
Who are InMed's strategic partners?
InMed collaborates with various pharmaceutical and biotechnology companies to advance its cannabinoid research and development efforts.
What financial outlook does InMed have?
InMed has shown strong financial performance, with revenue growth from its subsidiary BayMedica and a solid cash position to support its ongoing operations.
What diseases does InMed target?
InMed targets diseases with high unmet medical needs, including epidermolysis bullosa, glaucoma, Alzheimer's disease, and age-related macular degeneration.
How does InMed contribute to the health and wellness industry?
Through its subsidiary BayMedica, InMed supplies rare cannabinoids to brands within the health and wellness industry, driving revenue growth and expanding market reach.
Where can I find more information about InMed?
For more information, visit InMed's websites at www.inmedpharma.com and www.baymedica.com.
What are the future plans for InMed's product development?
InMed plans to further develop its proprietary small molecule drug candidates, continue preclinical and clinical trials, and explore new therapeutic areas.
InMed Pharmaceuticals Inc. Common Shares
Nasdaq:INM
INM Rankings
INM Stock Data
3.40M
713.92k
0.87%
Biotechnology
Pharmaceutical Preparations
United States of America
VANCOUVER